Chr. Hansen Holding — Board/Management Information 2017

Jan 6, 2017

Hoersholm, 2017-01-06 07:58 CET (GLOBE NEWSWIRE) --

Company announcement No. 01/2017

After more than 25 years with Chr. Hansen and 11 years in Executive Management,
Knud Vindfeldt will step down from the Executive Board of Chr. Hansen Holding
A/S on 28 February 2017.

Knud Vindfeldt joined Chr. Hansen in 1991 and was appointed member of the
Executive Board of Chr. Hansen Holding A/S and head of the Cultures & Enzymes
Division in 2005, and was further appointed COO and Deputy CEO in 2016. After
February, Knud will continue to support Chr. Hansen in the role of advisor to
the CEO for a period of six months.

Cees de Jong, CEO of Chr. Hansen, says: “Knud has been one of the key drivers
behind the success of Chr. Hansen in the dairy market, and he has relentlessly
pushed for continued improvements in our strategic, operational and financial
performance. The results delivered by the Food Cultures & Enzymes Division
(FC&E) speak for themselves; since 2005, both revenue and EBIT margin have more
than doubled.

“With the transfer of the commercial responsibility for FC&E to Christoffer
Lorenzen in April last year, the recent recruitment of Thomas Schäfer as Chief
Scientific Officer and, today, with the promotion of Torsten Steenholt to
Executive Vice President, Global Operations and member of the Corporate
Leadership Team, we have ensured Knud’s succession. On behalf of the entire
Chr. Hansen organization, I would like to thank Knud for his exceptional
contribution to Chr. Hansen and wish him all the best for the future.”

Knud Vindfeldt says: “Chr. Hansen is a truly great company and it has been a
fantastic journey, which I am proud to have been part of. The company is in
better shape than ever, delivering solid results. With such strong successors
in place, I feel confident that this is a natural time for me to step down. In
the coming months, we will ensure a good handover.”

Following this change, the Executive Board will consist of CEO Cees de Jong and
CFO Søren Westh Lonning. In addition, and as previously announced, Thomas
Schäfer will join Chr. Hansen as CSO and member of the Executive Board in due
course.

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations
Tel.: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel.: +45 5339 2384

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient
solutions for the food, nutritional, pharmaceutical and agricultural
industries. The products include cultures, enzymes, probiotics and natural
colors, and all solutions are based on strong research and development
competencies coupled with significant technology investments. Revenue in the
2015/16 financial year was EUR 949 million. The company has more than 2,700
dedicated employees in 30 countries and main production facilities in Denmark,
France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on
Nasdaq Copenhagen A/S. For further information, please visit
www.chr-hansen.com.